TAO Synergies (TAOX) Cash from Investing Activities (2020 - 2025)
TAO Synergies' (TAOX) quarterly Cash from Investing Activities came in at -$11.3 million in Q4 2025, up 13.36% quarter-over-quarter from -$13.1 million in Q3 2025.
Analysis
TAO Synergies (TAOX) Cash from Investing Activities (2020 - 2025) Analysis & Trends
TAO Synergies (TAOX) has reported Cash from Investing Activities for 5 consecutive years, with -$11.3 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Cash from Investing Activities changed N/A year-over-year to -$11.3 million; the trailing twelve-month figure through Dec 2025 stood at -$24.4 million (down 2339.47% YoY), and the FY2025 full-year result was -$28.9 million, down 2789.47% from the prior year.
- Cash from Investing Activities grew to -$11.3 million in Q4 2025 per TAOX's latest filing, from -$13.1 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$669.0 in Q2 2023 and bottomed at -$13.1 million in Q3 2025.
- Historically, Cash from Investing Activities has averaged -$3.0 million across 4 years, with a median of -$500000.0 in 2024.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities tumbled 93401.64% in 2023, then plunged 24433.86% in 2024.
- Over 4 years, Cash from Investing Activities stood at -$2139.0 in 2022, then sank by 93401.64% to -$2.0 million in 2023, then soared by 75.0% to -$500000.0 in 2024, then slumped by 2164.9% to -$11.3 million in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$11.3 million, -$13.1 million, and -$500000.0 for Q4 2025, Q3 2025, and Q2 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.37 Bn | 197.38 Bn | 7.24 Bn | -569.00 Mn |
| 2 | Gilead Sciences | 181.12 Bn | 177.94 Bn | 6.22 Bn | -10.35 Bn |
| 3 | Vertex Pharmaceuticals | 132.11 Bn | 124.26 Bn | 2.84 Bn | -45.80 Mn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | -92.70 Mn |
| 5 | Argenx Se | 61.69 Bn | 56.50 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.62 Bn | 49.48 Bn | 52.00 Mn | 329.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.14 Bn | 30.84 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | -3.84 Bn |
| 9 | Roivant Sciences | 30.09 Bn | 30.09 Bn | 1.16 Mn | 281.26 Mn |
| 10 | TAO Synergies | 30.79 Mn | 30.79 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -11.32 Mn |
| Sep 30, 2025 | -13.07 Mn |
| Jun 30, 2024 | -500,000.00 |
| Mar 31, 2024 | -500,000.00 |
| Dec 31, 2023 | -2.00 Mn |
| Jun 30, 2023 | -669.00 |
| Mar 31, 2023 | -2,038.00 |
| Dec 31, 2022 | -2,139.00 |
| Sep 30, 2022 | -2,246.00 |
| Jun 30, 2020 | -2,814.00 |
| Mar 31, 2020 | -2,599.00 |